ArticleImmunotherapy2025
Subcorneal pustular dermatosis triggered by adalimumab in a patient with ankylosing spondylitis and Crohn's disease.
Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor-alpha (TNF-α) inhibitors, notably adalimumab, represent a cornerstone in managing chronic inflammatory disorders such as ankylosing spondylitis and Crohn's disease. Despite their therapeutic efficacy, paradoxical dermatologic adverse events, including pustular eruptions, have been occasionally documented. This report presents the case of a 62-year-old Caucasian female patient who developed erythematous-pustular lesions following prolonged exposure to adalimumab. Histopathologic assessment confirmed subcorneal pustular dermatosis (SPD), characterized by subcorneal neutrophilic accumulations and focal spongiosis. Discontinuation of adalimumab and initiation of systemic corticosteroids alone led to prompt clinical resolution. This case contributes to the limited literature on anti-TNF-induced SPD, emphasizing the critical role of early recognition and interdisciplinary intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.